MX336242B - Uso de los compuestos a base de lantibioticos del tipo b que tienen actividad antimicrobiana. - Google Patents

Uso de los compuestos a base de lantibioticos del tipo b que tienen actividad antimicrobiana.

Info

Publication number
MX336242B
MX336242B MX2010000492A MX2010000492A MX336242B MX 336242 B MX336242 B MX 336242B MX 2010000492 A MX2010000492 A MX 2010000492A MX 2010000492 A MX2010000492 A MX 2010000492A MX 336242 B MX336242 B MX 336242B
Authority
MX
Mexico
Prior art keywords
type
lantibiotic
based compounds
antimicrobial activity
prophylaxis
Prior art date
Application number
MX2010000492A
Other languages
English (en)
Inventor
Michael John Dawson
Jesus Cortes Bargallo
Sjoerd Nicolaas Wadman
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of MX336242B publication Critical patent/MX336242B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento o profilaxis de una infección microbiana del colon o del intestino inferior en un sujeto, el método comprende administrar al sujeto un lantibiótico del tipo B. En particular, la invención proporciona métodos para el tratamiento o profilaxis de una infección provocada por Clostridium difficile. Los lantibióticos del tipo B pueden incluir compuestos seleccionados del grupo que consiste de mersacidina, actagardina, plantaricina, planosporicina, ruminococcina, antibiótico 10789, michiganina y haloduracina, y derivados y variantes de los mismos.
MX2010000492A 2007-07-18 2008-07-18 Uso de los compuestos a base de lantibioticos del tipo b que tienen actividad antimicrobiana. MX336242B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0714030.4A GB0714030D0 (en) 2007-07-18 2007-07-18 The use of type-B lantibiotic-based compounds having antimicrobial activity
PCT/GB2008/002463 WO2009010763A1 (en) 2007-07-18 2008-07-18 The use of type-b lantibiotic-based compounds having antimicrobial activity

Publications (1)

Publication Number Publication Date
MX336242B true MX336242B (es) 2016-01-13

Family

ID=38476567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000492A MX336242B (es) 2007-07-18 2008-07-18 Uso de los compuestos a base de lantibioticos del tipo b que tienen actividad antimicrobiana.

Country Status (10)

Country Link
US (1) US8575094B2 (es)
EP (1) EP2178552A1 (es)
JP (1) JP5613563B2 (es)
CN (1) CN101754769B (es)
BR (1) BRPI0814034A2 (es)
CA (1) CA2693047A1 (es)
EA (1) EA021628B1 (es)
GB (1) GB0714030D0 (es)
MX (1) MX336242B (es)
WO (1) WO2009010763A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
EA017564B1 (ru) * 2007-09-12 2013-01-30 Тарганта Терапьютикс Корп. Способ ингибирования клостридиум диффициле введением оритаванцина
CA2749278A1 (en) 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체
FR2954140A1 (fr) * 2009-12-17 2011-06-24 Oreal Compositions cosmetiques ou dermatologiques a base de bacteriocines et de prebiotiques
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
WO2011095768A1 (en) * 2010-02-02 2011-08-11 Novacta Biosystems Limited Lantibiotic salts
US20130171252A1 (en) * 2010-07-14 2013-07-04 Novacta Biosystems Limited Formulation Comprising a Type B Lantibiotic
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
EP3111949A1 (en) * 2015-07-01 2017-01-04 Deinobiotics New bicyclic lipopeptide, preparation and use as antimicrobial agent
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
WO2023164788A1 (zh) * 2022-03-01 2023-09-07 中国科学院深圳理工大学(筹) 羊毛硫抗生素高通量筛选方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (es) * 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
EP0700998B1 (en) * 1994-09-12 2003-11-26 Aventis Pharma Deutschland GmbH Recombinant mersacidin and a method for production
EP0833657B1 (en) * 1995-06-23 2003-08-27 AMBI Inc. A method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
DE19745583A1 (de) * 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
JP2006502713A (ja) 2002-10-10 2006-01-26 モリケム メディシンズ， インコーポレイテッド デュラマイシンをコードする核酸
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ES2281808T3 (es) * 2003-07-18 2007-10-01 Vicuron Pharmaceuticals, Inc. Antibiotico 107891, sus factores a1 y a2, composiciones y sales farmaceuticamente aceptables y uso del mismo.
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
WO2007036706A1 (en) * 2005-09-27 2007-04-05 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
US20090170562A1 (en) * 2005-09-28 2009-07-02 Nokia Corporation Speed dial configuration of a mobile terminal for a mobile telecommunications network from a remote service
GB0600928D0 (en) * 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
WO2008151434A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
KR20110086582A (ko) 2008-11-24 2011-07-28 센티넬라 파마세티컬즈, 인크. 항균활성이 강화된 란티바이오틱 카르복시아미드 유도체
CA2749278A1 (en) 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
KR20110122139A (ko) 2009-02-04 2011-11-09 노박타 바이오시스템스 리미티드 액타가르딘 유도체

Also Published As

Publication number Publication date
EP2178552A1 (en) 2010-04-28
EA200971102A1 (ru) 2010-08-30
US8575094B2 (en) 2013-11-05
CN101754769A (zh) 2010-06-23
CA2693047A1 (en) 2009-01-22
JP2010533695A (ja) 2010-10-28
GB0714030D0 (en) 2007-08-29
BRPI0814034A2 (pt) 2015-02-18
CN101754769B (zh) 2015-09-09
EA021628B1 (ru) 2015-07-30
US20090203583A1 (en) 2009-08-13
WO2009010763A1 (en) 2009-01-22
JP5613563B2 (ja) 2014-10-22

Similar Documents

Publication Publication Date Title
MX336242B (es) Uso de los compuestos a base de lantibioticos del tipo b que tienen actividad antimicrobiana.
Garrido et al. Antimicrobial resistance in enterococci
EP1576120A4 (en) ANTI-MICROBIAL COMPOUNDS FROM I BACILLUS SUBTILIS / I AND USE AGAINST ANIMAL AND HUMAN PATHOGENS
Lerma et al. Role of EfrAB efflux pump in biocide tolerance and antibiotic resistance of Enterococcus faecalis and Enterococcus faecium isolated from traditional fermented foods and the effect of EDTA as EfrAB inhibitor
WO2007130655A3 (en) Phage derived antimicrobial activities
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
HK1128286A1 (en) Heterocyclylalkyl derivatives as inhibitors of histone deacetylase
NZ618571A (en) Peptides and their use
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2008041966A3 (en) Broad spectrum antibacterial compounds
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
EP3216798A3 (en) Ketolide compounds
MX338032B (es) Composicion nematocida que comprende bacillus subtilis y bacillus licheniformis.
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
NZ588999A (en) Compositions for enhancing the antibacterial activity of myeloperoxidase and methods of use thereof
DK2069473T3 (da) Antibiotiske antimikrobielle midler og fremgangsmåder til deres anvendelse
WO2007117680A3 (en) Methods and compositions for treating bacterial infection
MX2011008043A (es) Derivados de actagardina.
TW200716162A (en) Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
WO2009022185A3 (en) 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
WO2010134827A9 (en) Extended acting oxygen generating composition for treating microbial infections
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
MX2007009059A (es) Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos.
ATE523204T1 (de) Cd44v6-peptide als bakterielle infektionsinhibitoren